
National Healthcare Safety Network (NHSN) LTCF COVID-19 Module Training

LTCF COVID-19 Module: Therapeutics Pathway

Date: June 2021

Presenter: Molly Stillions RN, MSN Nurse Infection Preventionist, Division of Healthcare Quality Promotion,

Centers for Disease Control and Prevention, Surveillance Branch





cdc.gov/coronavirus






Apply the NHSN criteria to surveillance data reporting in the Therapeutics pathway of the LTCF COVID-19 Module



LTCF COVID-19 Module: 5 Surveillance Pathways for Data Reporting

Optimizing Timely, Standardized Data Collection to Characterize National Impact, Inform Ongoing Activities, and Direct Resources





Tips for NHSN Reporting in the Therapeutics Pathway

- Report in the pathway once during the reporting week
- Report only NEW counts since the last time counts were collected for reporting to NHSN
- Enter a 0 for any Therapeutics that were not given during the reporting week

Important! Facilities reporting to NHSN do still need to follow state and local public health reporting requirements




One Stop Browsing for NSHN LTCF COVID-19 Module Resources

Visit <u>NSHN LTCF COVID-19 Module web-page</u> for reporting resources

LTCF COVID-19 Module

<u>CDC's NHSN</u> provides healthcare facilities, such as long-term care facilities (LTCFs), with a secure reporting platform for reporting outcomes and process measures in a systematic way. Reported data are immediately available for use in strengthening local and national surveillance, monitoring trends in infection rates, assisting in identifying resource insecurities, and informing progress toward infection prevention goals.



The <u>NHSN Long-term Care Facility Component</u> supports the nation's COVID-19 response through the LTC Module. Facilities eligible to report data to NHSN's COVID-19 Module include nursing homes/skilled nursi for the developmentally disabled, and assisted living facilities.

Data reported into the LTCF COVID-19 Module **Surveillance Reporting Pathways** facilitate assessment of I COVID-19 through facility reported surveillance data. Examples of data reported in the pathways include

- · Counts of residents and facility personnel newly positive for COVID-19 based on viral test results.
- · COVID-19 vaccination status of residents newly positive for COVID-19.
- · Re-infections in residents and facility personnel previously infected with COVID-19.
- · COVID-19 related death counts among residents and facility personnel.
- Staffing shortages.

Enhancing Data Security
Training
Data Collection Forms & Instructions
Resources

Get NHSN COVID-19 Updates

For continued NHSN COVID-19 updates, please enter your email address, NHSN facility and group users do not need to sign up, you will receive them automatically.

Email

https://www.cdc.gov/nhsn/ltc/covid19/index.html

Availability and survey consists use of newconal protective equipment (DDP) and alcohol based band of



COVID-19 Data Dashboard
CDC COVID-19 Info Get the latest information from the CDC about COVID-19

Nursing Home

	Α.	0	_
-	А	()	
	•	4	-

+

+

+

POC Testing Reporting Tool FAQs
POC Testing Reporting Reporting Tool FAQs
POC Testing Reporting Reporting Reporting Tool FAQs
POC Testing Reporting Re

CMS Requirements

View Data Collection Forms and Form Instructions

		-	
	н	SI	N
NATIONAL			
SAFET	/ NET	WOR!	C

OMB Approved OMB No. 0920-1317 Exp. Date 01/31/2024 www.cdc.gov/nhsn

COVID-19 Module Long Term Care Facility: Resident Therapeutics

Page 1 of 1	*Required to save; **Conditional
NHSN Facility	ID: CMS Certification Number (CCN):
Facility Name	Facility Type:
"Date for which	h counts are reported: / / Date Created: / /
	counts for the below questions only one calendar day during the reporting week and include only new the previously reported counts. If the count is zero, a ¹⁰ must be entered as the response. A blank response is equivalent to missing data.
	For each therapeutic listed, enter number of residents who received the therapeutic at this facility or elsewhere <u>during the reporting week</u> :
	Therapeutic: Casirivimab plus Imdevimab (Regeneron)
	How many residents were treated from stock stored at this facility?
	**How many residents were treated from stock that was stored at another facility, such as an infusion center?
	Therapeutic: Bamlanivimab plus etesevimab (Lilly)
	How many residents were treated from stock stored at this facility?
	**How many residents were treated from stock that was stored at another facility, such as an infusion center?
	Therapeutic: Bamlanivimab alone (Lilly)
	How many residents were treated from stock stored at this facility?
	**How many residents were treated from stock that was stored at another facility, such as an infusion center?




March 2021 (v.2)

Instructions for Completion of the COVID-19 Long-term Care Facility (LTCF) Resident Therapeutics Form (CDC 57.158)

	Instructions for Form Completion
NHSN Facility ID #	The NHSN-assigned facility ID will be auto-generated by the system.
CMS Certification Number (CCN)-may be referred to as participation number	Auto-generated by the computer, if applicable, based on the CCN entered during NHSM registration or last updated, if previously edited. Please see <u>NHSN CCN Guidance</u> document for instructions on how to add a new CCN or edit an existing CCN.
Facility Name	Auto- generated by the system based on the facility name previously entered during NHSN registration.
Date for which counts are reported	Required. Select the date on the calendar in which the counts are being reported in the NHSN LTCF COVID-19 Module- <i>Therapeutics Pathway</i> .
Facility Type	Auto generated based on the facility type selected during NHSN enrollment. Selections include: LTC-ASSIT – Assited Living Residence LTC-ASSIT – Assited Living Residence LTC-ASSIT – Assited Living Residence LTC-ASSIT LTC-ASSIT Joshed (referred to by CMS as "Intermediate Care Facilities for Individuals with Intellectual Disabilities (ICFA/IID [®]). LTC-SKILINURS – Skilled Nursing Facility* *Includes both skilled nursing facilities and nursing homes Please see NHSN Guidance document for instructions on <u>How to Correct</u> Your Facility Type if the autogenerated information is incorrect.
Date Created	Auto generated based on the first calendar date and time that a user manually enters and saves data or the date the facility first submits a CSV file for a specific pathway. <i>Note:</i> The date and time will automatically


https://www.cdc.gov/nhsn/pdfs/covid19/ltcf/57.144 -toi-508.pdf

NHSN Home Page > COVID-19 > Pathway Data Reporting> Calendar View Opens





Use Arrow Icons to Navigate Dates



Options for Therapeutics Pathway Data Reporting





Importing CSV files

Manual Data entry

Groups; Facility



Resources for Importing Data

Visit NSHN LTCF COVID-19 Module web-page

LTCF COVID-19 Module

CDCs.NMSh provides healthcare facility as long-term care facilities (CFG), will reporting platform for reporting outco process measures in a systematic may data are invertightely available for use strengthening local and national surv- monitoring trends in infection rates, a dentifying resource insecurities, and i progress toward infection prevention.	ha society Reported Mining Morring	
The <u>NHSN Long term Care Facility Cor</u> Module. Facilities eligible to report dat for the developmentally disabled, and		+
Data reported into the LTCF COVID-19 COVID-19 through facility reported sur	Enhancing Data Security	+
Counts of residents and facility per COVID-19 vaccination status of resi	Training	+
Re-infections in residents and facili COVID-19 related death counts am	but concession of the ansatures	•
Staffing shortages.	Resources	4 >+

- CSV data file templates for facility and groups
- Guidance documents with importing requirements [variable names, values, format, description]



https://www.cdc.gov/nhsn/ltc/covid19/index.html

Importing Data Resources

+

+

- Facility Level CSV File Templates for Surveillance Reporting Pathways How to Upload COVID-19 CSV Data Files [PDF - 1 MB] - February 4. 2021
 - Resident Impact and Facility Capacity Template. E [CSV 1 KB] February 4, 2021
 - Staff and Personnel Impact Template E [CSV 1 KB] November 23,
 - Supplies and Personal Protective Equipment Template [CSV - 1 KB]
 - Ventilator Capacity and Supplies Template E (CSV 1 KB)
 - Resident Therapeutics Template E [CSV 1 KB] February 4, 2021
- Group Level CSV File Templates for Surveillance Reporting Pathways
 - Viewing and Uploading COVID-19 CSV Data Files
 [PDF 1 MB] -February 4, 2021
 - Resident Impact and Facility Capacity Template
 [CSV 1 KB] -February 4, 2021
 - Staff and Personnel Impact Template. III (CSV 1 KB) November 23. 2020
 - Supplies and Personal Protective Equipment Template [CSV - 1 KB]
 - Ventilator Capacity and Supplies Template E [CSV 1 KB]
 - Resident Therapeutics Template
 (CSV 1 KB) February 4, 2021

CSV Template and File Layout for CSV Upload

treatfromother

í	POSSIBLE	E DATA LOSS		-	-	ou save this workbook in an Excel file format.	i t			
A1		- : >		fx						erapeutics file t for csv upload
$\langle \rangle$	Not set				Public	👺 NHSN			Tayou	t for csv uprodu
	А	В	С	D	E	SAFETY NETWORK				
1	collection	therapeut	treatfrom	treatfromo	ther		ting CO	VID-19 Usin	g a .csv Fil	le for LTC Therapeutics
2	########	BAMLAN	3	1		Summary Data				
3	########	CASIMDE\	4	2		1. NHSN COVID-19 LTC The	rapeutics Im	port File Format		
4	########	BAMETES	5	3						
5						Field	Requiremen	tValues	Format [†]	Description of Field
	-					collectionDate	Required	-	mm/dd/yyyy	Date for which patient counts are reported:
6		Therap	eutics			therapeutic	Required	BAMLAN – for	-	Therapeutic administered
7 8	Те	emplate uplo						Bamlanivimab (Lily) CASIMDEV – for Casirivmab/imdevimab (Regeneron) BAMETES for Bamlanivimab/etesevimab (Lilly)		Note: Use a separate row for each Therapeutic. If a facility is administering all three therapeutics there will be 3 rows for the facility.
						treatfromfac	Conditionally	Must be <=3000	Must be a whole	How many residents were treated from stock stored at this faci

Required

Required

Conditionally

Must be <=3000

number

number

Must be a whole

How many residents were treated from stock that was stored at


another facility, such as an infusion center?




Manual Data Entry Therapeutics Pathway

NHSN COVID-19 Module





COVID-19 Module: Therapeutics Pathway



Therapeutics Pathway

"Current Census" is required before saving data entered in any pathway



BEDS (enter on first survey only, unless the total bed count has changed)
URRENT CENSUS: Total number of beds that are occupied on the reporting calendar day



What is a Therapeutic?

- Therapeutic is defined as a treatment, therapy, or drug. Monoclonal antibodies are examples of anti-SARS-CoV-2 antibody-based therapeutics used to help the immune system recognize and respond more effectively to the COVID-19 virus.
 - Casirivimab + imdevimab (Regeneron)
 - Bamlanivimab + etesevimab (Lilly)
- Sotrovimab will be added to the NHSN application in the future, the date has not yet been determined.





These therapeutics are not vaccines or related to vaccinations .

Therapeutics Pathway

for which counts are reported	: 05/12/2021	Facility Type: LTC-S	SKILLNURS
esident Impact and Facility Ca	apacity Staff and Personnel Impact	Supplies and Personal Protective Equipment	Ventilator Capacity and Supplie
nerapeutics			
the count is zero, a "0" must b	e entered as the response. A blank respon	<u>the reporting week</u> and include only <u>new counts</u> si se is equivalent to missing data. eutic at this facility or elsewhere during the reporting y	
			Bamlanivimab
Therapeutic	How many residents were treated from stock stored at this facility?	How many residents were treated from stock that was stored at another	alone (Lilly) will
		facility, such as an infusion center?	no longer be
Casirivimab/imdevimab (Regeneron)			available to
Bamlanivimab/etesevimab (Lilly)			report data
Bamlanivimab alone (Lilly)			beginning in
			July 2021
landatory fields marked with			
		Save Cancel	
		Save	

Bamlanivimab (Lilly)

★ The Emergency Use Authorization for Bamlanivimab (Lilly) has been revoked.

★ Bamlanivimab (Lilly) will no longer be available in the Therapeutics Pathway for data reporting beginning in July of 2021.

This option will be		Therapeutic	How many residents were treated from stock stored at this facility?	How many residents were treated from stock that was stored at another facility, such as an infusion center?
removed from the	,	Casirivimab/imdevimab (Regeneron)		
pathway		Bamlanivimab/etesevimab (Lilly)		
		Bamlanivimab alone (Lilly)		



Bamlanivimab plus Etesevimab (Lilly): Paused in Various States

★ It is recommended that several states use the alternative authorized monoclonal antibody therapy, casirivimab and imdevimab (Regeneron).

★ Data is showing that bamlanivimab and etesevimab administered together are not active against the P.1 variant





Therapeutics Pathway

Respond to two questions for each listed therapeutic

For this reporting week, how many residents were administered the therapeutic based on **stock stored at your LTCF?**

Example: infusion nurse comes to the LTCF to administer therapeutic that was available and stored at the LTCF For this reporting week, how many residents were administered the therapeutic based on stock that was stored at another facility?

Example: infusion nurse brings therapeutic to the LTCF to administer to resident



Therapeutics Pathway: Case Study 1 – DHQP Nursing Home

Therapeutic pathway data are reported on Fridays of each reporting week for DHQP Nursing Home

For the reporting week of May 14th, the following residents received a therapeutic:

- Resident A received Casirivimab plus imdevimab (Regeneron) on 5/10 from stock stored at the LTCF.
- Resident B is transferred to the hospital where the resident received Casirivimab plus imdevimab (Regeneron) after admission, on 5/11.
- Resident C received an infusion of bamlanivimab plus etesevimab (Lilly) on 5/12 from an infusion nurse who brought the therapeutic to the LTCF from an outside pharmacy.
- Resident D received bamlanivimab plus etesevimab (Lilly) at the local emergency department on 5/12.



No other residents received therapeutics during this reporting week

Therapeutics Pathway: Case Study 1, data reported for DHQP Nursing Home for the reporting week

esident Impact and Facility Ca	pacity Staff and Personnel Impact	Supplies and Personal Protective Equipment	Ventilator Capacity and Supplies
herapeutics			
the count is zero, a "0" must be	e entered as the response. A blank respon	nse is equivalent to missing data.	
or each therapeutic listed, enter n	number of residents who received the therap How many residents were treated from stock stored at this facility?	How many residents were treated from stock that was stored at another facility, such as an infusion center?	week:
	How many residents were treated	How many residents were treated	week:
Therapeutic Casirivimab/imdevimab	How many residents were treated from stock stored at this facility?	How many residents were treated from stock that was stored at another facility, such as an infusion center?	week:





Therapeutics Pathway: Case Study 1, data reported for DHQP Nursing Home for the reporting week

	5/14/21		raciii	ty Type: LTC-SI	
ident Impact and Facility Ca	pacity Staff and F	Personnel Impact	Supplies and Personal Protect	ve Equipment	Ventilator Capacity and Supplies
erapeutics					
ne count is zero, a "O" must be	e entered as the respor	nse. A blank respons	<u>he reporting week</u> and include onl e is equivalent to missing data. utic at this facility or elsewhere durin		ce the previously reported counts.
			nas record a secondensa a record a production de construction de la construction de la construction de la const		
Therapeutic	How many resident from stock stored a	Error		ther ?	
Casirivimab/imdevimab (Regeneron)	* 1		SUS: Total number of beds		
Bamlanivimab/etesevimab (Lilly)	* 0	that are occupied on the reporting calendar day is required.			
Bamlanivimab alone (Lilly)	* 0				
			OK		

Save


Cance



Therapeutics Pathway: Case Study 1, data reported for DHQP Nursing Home for the reporting week, continued

COVID-19 Data					
e for which counts are reported: 5/14/21		Facility Type: LTC-SKILL			
esident Impact a	and Facility Capacity	Staff and Personnel Impact	Supplies and Personal Protective Equipment	Ventilator Capacity and Supplies	Therapeutics
ate Created:					
ounts should be re	esponse is equivalent to m ty		v counts for the calendar day (specifically, since counts w should be answered one calendar day during the reporti ed count has changed)		0" must entered as t







Therapeutics Pathway: Case Study 2 – DHQP Nursing Home

Therapeutic pathway data are reported on Fridays of each reporting week for DHQP Nursing Home

For the reporting week of May 21st, the following residents received a therapeutic:

- Resident A received Bamlanivimab and etesevimab (Lilly) on 5/18 from stock stored at the LTCF.
- Resident B received Casirivimab and imdevimab (Regeneron) at an infusion center in which the stock came from the infusion center and was administered in the infusion center on 5/19
- Resident C received an infusion of Bamlanivimaband etesevimab (Lilly) on 5/17 from an infusion nurse who brought the therapeutic from an outside pharmacy.

No other residents received therapeutics during this reporting week



Therapeutics Pathway: Case Study 2, data reported for DHQP Nursing Home for the reporting week

for which counts are reported: 5/21/21		Facility Type: LTC-SKILLNURS	
esident Impact and Facility Ca	apacity Staff and Personnel Impact	Supplies and Personal Protective Equipment	Ventilator Capacity and Supp
nerapeutics			
	w questions only <u>one calendar day during</u> e entered as the response. A blank respon		
the count is zero, a "0" must be	e entered as the response. A blank respon number of residents who received the therap How many residents were treated	nse is equivalent to missing data. Deutic at this facility or elsewhere during the reporting w How many residents were treated	
the count is zero, a "0" must be or each therapeutic listed, enter r	e entered as the response. A blank respon number of residents who received the therap	nse is equivalent to missing data.	
the count is zero, a "0" must be or each therapeutic listed, enter r	e entered as the response. A blank respon number of residents who received the therap How many residents were treated	nse is equivalent to missing data. Deutic at this facility or elsewhere during the reporting w How many residents were treated from stock that was stored at another	
the count is zero, a "0" must be or each therapeutic listed, enter r Therapeutic Casirivimab/imdevimab	e entered as the response. A blank respon number of residents who received the therap How many residents were treated from stock stored at this facility?	How many residents were treated from stock that was stored at another facility, such as an infusion center?	

Mandatory fields marked with *





Therapeutics Pathway: Case Study 2, data reported for DHQP Nursing Home for the reporting week

COVID-19 Data				
e for which counts are reported: 5/2	1/21	Facility Type: LTC-SKILLNURS		
Resident Impact and Facility Capacity	Staff and Personnel Impact	Supplies and Personal Protective Equipment	Ventilator Capacity and Supplies	
Therapeutics				
If the count is zero, a "0" must be entered	any r Message	utic at this facility or elsewhere during the reporting w		
Casirivimab/imdevimab * 0 (Regeneron)				
Bamlanivimab/etesevimab * 1 (Lilly)				
Bamlanivimab alone (Lilly)		ОК		
Mandatory fields marked with *				
			Save Can	

Take aways and reminders



Do not report cumulative counts. (for example, counts already reported to NHSN for the previous reporting week)



Therapeutics in this pathway are NOT vaccines and should not be confused with vaccine counts.



Takeaways and reminders

The NHSN application will be updated accordingly with changes in available therapies



If 0 residents received therapeutics during the reporting week, then please enter a 0 for all listed therapeutic options



A response is required for both data elements for each Therapeutic administered during the reporting week




NHSN Helpdesk

★ If you have further questions and or concerns, please send an e-mail to <u>NHSN@cdc.gov</u>

* Add a brief description of your inquiry in the subject header





For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

